Hims & Hers Health news

The company faces FTC allegations of sharing sensitive health information with third parties, deceptive billing practices, and undisclosed charges. The stock experienced a significant 14.73% decline on the news, and a securities class action lawsuit has been filed against the company and its executives for failing to disclose material information.

Company faces serious allegations of deceptive health data sharing with advertisers, unauthorized subscription billing, and regulatory violations. Stock crashed 14.7% on complaint announcement, resulting in $970 million market cap loss. Securities class action lawsuit filed with substantial investor losses.

Company faces FTC lawsuit alleging deceptive privacy practices and misleading billing disclosures. Stock declined 14.73% on the news, and a securities fraud class action has been filed against the company and its executives for failing to disclose material information.

The company faces FTC allegations of privacy violations, consumer deception regarding billing practices, and regulatory scrutiny. Stock price declined 14.73% following the announcement, and a securities fraud class action lawsuit has been filed against the company.

The company is the subject of a securities class action lawsuit alleging material misstatements regarding consumer data sharing with third-party platforms, improper prescription charging practices, and undisclosed regulatory risks. These allegations suggest significant corporate governance and compliance failures that resulted in investor losses.

The company faces a securities fraud class action lawsuit alleging material misstatements about privacy practices, an FTC lawsuit for sharing customer medical data with advertisers, and a significant stock price decline of 14.73%. These developments indicate serious regulatory and legal challenges that negatively impact investor confidence.

The company faces regulatory action from the FTC and a class action lawsuit for allegedly sharing sensitive health information with advertising platforms without proper disclosure and engaging in deceptive billing practices. The stock declined 14.73% on the FTC announcement, indicating significant investor concern about legal and reputational risks.

Stock declined 6.7% versus broader market loss of 0.76%, significantly underperforming. Despite positive earnings growth expectations, consensus EPS estimates have dropped 55% in the past 30 days, indicating deteriorating investor confidence and resulting in a Hold rating rather than a Buy recommendation.

The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding consumer data sharing with third-party platforms, improper prescription charging practices, and undisclosed regulatory risks. These allegations suggest significant corporate governance and compliance failures that resulted in investor losses.

Company faces securities fraud class action lawsuit for material misstatements about privacy practices. FTC filed criminal complaint alleging deceptive and unlawful sharing of patient health data with third-party advertisers. Stock price declined 14.73% ($4.32 per share) on the news, indicating significant investor loss and regulatory scrutiny.

The company has surpassed three million members, doubled in six months, and an analyst predicts 56% gains by end of 2026. The Motley Fool recommends the stock and views the healthcare industry as ripe for disruption, suggesting confidence in the company's growth trajectory and market opportunity.

The company faces multiple regulatory lawsuits from the FTC and state authorities alleging deceptive business practices including unauthorized sharing of health data, misleading subscription charges, and difficult cancellation processes. A class action lawsuit was filed, and the stock declined 14.73% following the FTC action announcement.

Company faces FTC lawsuit alleging deceptive practices including undisclosed immediate prescription charges, difficult subscription cancellations, and unauthorized sharing of health data with third parties. Stock declined 14.73% following lawsuit announcement, and investors are seeking recovery through class action litigation.

The company faces a securities class action lawsuit alleging false statements about privacy practices and billing transparency. The FTC filed a separate lawsuit claiming deceptive practices including unauthorized sharing of health data with Meta and Snap, and misleading billing practices. Stock declined 15% on the FTC announcement, indicating significant investor harm and reputational damage.

The analyst provides a bullish price target with 55.7% upside potential, citing strong revenue growth (38% YoY), subscriber expansion (19% YoY), and rising revenue per subscriber (21% YoY). The company demonstrates operational momentum and potential for valuation rerating. However, the positive sentiment is tempered by acknowledgment of margin compression risks and the need for evidence that lower-margin businesses can improve profitability at scale.

Despite strong revenue growth (38.2% YoY) and raised guidance, the stock declined 7.7% due to earnings miss (10 cents loss vs. 7 cents consensus), significant gross margin contraction (1,256 bps), and surging operating expenses (48.4% increase). Analyst estimates have been revised downward 27.35%, and the company received a Hold rating with poor momentum and value scores.

While the stock outperformed the market on the trading day and shows strong near-term revenue growth expectations (49.34% YoY), the company has declined 12.78% over the past month. Additionally, full-year earnings estimates have declined significantly (-213.21%), and consensus EPS estimates have moved 118.75% lower over the last 30 days. The Hold rating reflects mixed signals between positive quarterly growth and concerning longer-term earnings revisions.

The company faces allegations of securities fraud, including misrepresentation of business practices (unauthorized data sharing, deceptive billing practices), and failure to disclose regulatory risks. These serious allegations of investor deception and potential regulatory penalties create significant negative sentiment.

The company is facing a securities class action lawsuit alleging material misstatements and omissions regarding consumer data privacy practices, deceptive billing practices, and undisclosed regulatory risks. These allegations suggest potential fraud and breach of investor trust, resulting in stock price decline and investor losses.

Company faced FTC lawsuit alleging deceptive practices including undisclosed immediate prescription charges, difficult subscription cancellations, and unauthorized sharing of health data with third parties. Stock fell 14.73% following the allegations.

The company faces regulatory scrutiny from the FTC for allegedly sharing consumer health information with third parties and engaging in deceptive billing practices. A securities fraud class action lawsuit has been filed, and the stock declined 14.73% on the announcement, indicating significant investor losses and reputational damage.

Company faces serious regulatory allegations including deceptive data sharing with third-party advertisers, unauthorized subscription billing, and dark pattern cancellation practices. Stock declined 14.7% on lawsuit announcement, and company faces potential significant financial penalties and reputational damage.

Strong growth drivers from weight-loss products (16% U.S. revenue growth), international expansion (17-fold surge), and AI integration are offset by significant concerns including 6-point gross margin decline, negative free cash flow of -$68M in Q2, and regulatory uncertainty around FDA peptide approvals. The Zacks Rank #3 (Hold) rating reflects balanced risk-reward.

Mixed signals: strong revenue growth (38.2% YoY) and raised guidance are positive, but significant margin compression (1,256 bps decline), operating losses, and widening loss estimates indicate profitability challenges. The company faces a trade-off between growth and near-term earnings, warranting a Hold rating.

The company faces a securities class action lawsuit and FTC enforcement action alleging deceptive practices including undisclosed immediate prescription charges, difficult subscription cancellations, and unauthorized sharing of consumer health information with third parties. The stock declined 14.73% on the news, reflecting significant investor concern about regulatory penalties and reputational damage.

The company is accused of securities fraud involving deceptive subscription enrollment practices and unauthorized charges to consumers. These allegations led to sharp stock price declines and significant investor losses, resulting in a class action lawsuit investigation.

Mixed signals: strong business fundamentals with 38% revenue growth and raised guidance are offset by significant legal headwinds from the FTC lawsuit ($47.5M contingency), stock down 40% YoY, and insider's non-discretionary sale. The non-discretionary nature of the transaction suggests no negative insider view, but regulatory uncertainty creates material risk that overshadows operational strength.

The insider sale is non-discretionary and tax-related rather than a bearish signal. The executive maintains substantial equity holdings and has significant RSU vesting through 2029, indicating confidence. However, the company faces near-term profitability challenges with $142 million net losses TTM, offset by strong revenue growth and successful international expansion post-acquisition.

The insider sale is routine and non-discretionary, driven by tax obligations rather than loss of confidence. However, the article highlights concerns about margin compression from specialty expansion, which presents a mixed outlook for long-term investors. The company's expansion into testosterone and peptides shows growth ambition but at the cost of profitability metrics.

Company faces FTC lawsuit for deceptive privacy practices involving unauthorized sharing of patient medical data with major tech platforms. Stock declined over 14% following the lawsuit announcement, and securities fraud investigations have been initiated by law firms on behalf of investors who experienced significant losses.

Company faces FTC lawsuit for deceptive privacy practices and unauthorized sharing of patient medical data with third parties. Stock price fell 14.73% following the announcement, indicating significant investor concern and potential legal liability.

The company is under investigation for alleged improper data sharing and tracking of users' private health information without meaningful consent, raising serious concerns about privacy and data protection practices. This represents potential regulatory violations and reputational damage.

Despite near-term overbought conditions suggesting a pullback, the company faces a significant long-term catalyst as employers drop GLP-1 coverage in 2027, which should drive patient migration to Hims & Hers' D2C platform. Revenue is forecast to grow from $2.89B (2026) to $3.45B (2027), with weight-loss business representing one-third of revenue. The recurring subscription model ($39-$149/month) positions the company well to capture displaced patients.

The article presents a balanced inquiry into whether the stock is undervalued without making a definitive recommendation. While it acknowledges volatility and recent earnings-related price movements, it frames the healthcare industry as ripe for disruption, suggesting potential opportunity, but the overall tone remains exploratory rather than bullish or bearish.

Stock down 18% since May 11 earnings call and 50% over one year. Company reported significant earnings and revenue misses. While international expansion via Eucalyptus acquisition presents growth opportunity, slowing revenue growth (94% in 2022 to 59% in 2025) and negative EPS growth (-3.77% in 2025) are concerning. High short interest (31.4%) and recent profitability gains are at risk from $1.15 billion debt obligations.

The company is raising $350 million in convertible debt, which presents significant risks including potential shareholder dilution or future cash obligations. The article emphasizes that the company has limited time to prove it's a growth company, suggesting market concerns about its trajectory and ability to service the debt.

While revenue growth remains solid, the company faces significant headwinds: net loss of $92.1M vs. prior year profit, adjusted EBITDA down 51% year-over-year, gross margins compressed 8 percentage points, and reduced EBITDA guidance. The shift to lower-margin branded products and aggressive spending on expansion are pressuring profitability, causing investor concern about the sustainability of the growth story.

Despite raising revenue guidance, the company faces significant margin compression with adjusted EBITDA declining 51% in Q1. The shift to lower-margin weight-loss drugs is pressuring profitability, and the analyst characterizes the current investment as speculative, dependent on uncertain FDA peptide approval.

Stock plunged 12% after Q1 earnings and revenue miss, marking fourth miss in five quarters. Down 50% over past year and 20% year-to-date. High short interest (31%) and significant insider selling ($125M) indicate weak confidence. However, raised full-year guidance and GLP-1 partnership showing strong traction provide some positive offset.

Stock crashed 12% due to significant earnings miss ($0.40 loss vs $0.01 expected profit) and revenue shortfall ($608M vs $616.5M expected). Sales growth of only 4% despite 9% subscriber growth indicates declining average revenue per user, suggesting weakening monetization.

Company is subject to class action lawsuit for alleged securities fraud, though specific details are not provided in the article excerpt.

Subject to a securities fraud class action lawsuit resulting from deceptive privacy and billing practices, with over 14% stock decline indicating significant investor losses.

Subject of a securities fraud class action lawsuit with a November 2, 2026 deadline for lead plaintiff motions, indicating alleged material misstatements or omissions to investors.

Subject of securities class action lawsuit covering August 2025 to July 2026 period, indicating alleged securities violations or misrepresentations during this timeframe.

Subject of securities class action lawsuit covering the period from August 4, 2025 to July 29, 2026, indicating investor losses during this timeframe.

Fell double digits on earnings miss

Announced major collaboration with Novo Nordisk to expand access to FDA-approved GLP-1 medications at affordable prices starting at $149/month, positioning itself as the largest global consumer health platform for medication access.

Mentioned as a competitor in the telehealth space. Enhanced CEO positions his company as offering a broader performance ecosystem compared to Hims' digital pharmacy model, but no negative developments are reported about Hims itself.

Amazon's GLP-1 entry targets pharmacy logistics rather than telehealth services, so Hims remains relatively insulated as a niche player, though faces indirect competitive pressure from Amazon's scale and pricing.

Pulled back hard from highs; LikeFolio data shows accelerating app downloads, growing purchases, and strong customer sentiment; regulatory noise creates opportunity despite short-term volatility

Expected to join the Wegovy subscription program later, positioning the company to capture additional market share in the growing obesity treatment telehealth sector.

Recently partnered with Novo Nordisk to offer FDA-approved GLP-1 weight-loss pill and injectable Wegovy in all dosages, positioning itself to benefit from increased accessibility and demand in the weight-loss treatment market.

Hims & Hers announced a strategic collaboration with Novo Nordisk to offer Wegovy in all dosages alongside other weight-loss medications and Ozempic at competitive pricing. This partnership expands their product offerings and market reach in the growing weight-loss drug category, positioning them favorably in the telehealth space.

Included in the top 10 most-shorted stocks, indicating significant short interest and negative sentiment from institutional investors.

Partnership with Novo Nordisk to distribute obesity drugs on its telehealth platform represents a high-growth distribution opportunity and strengthens its position as a chronic disease management platform.

Hims & Hers is mentioned as a competitive threat to Novo Nordisk in the weight-loss market, with Novo filing a lawsuit against the company, indicating escalating competitive tensions and regulatory challenges.